Drug Discovery & Development | Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies Motley Fool Seattle Genetics (NASDAQ: SGEN ) is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against cancer. Now AbbVie (NYSE: ABBV ) has ... Seattle Gentics-AbbVie Deal Expanded Seattle Genetics, AbbVie Broaden Partnership |
